COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”

Kapar, Berkay; ŞİMŞEK, DENİZ; SAINGUVEN, GULAY

doi:10.5578/flora.20219902

COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”

Berkay KAPAR, (Hacettepe Üniversitesi, Tıp Fakültesi Hastanesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Deniz ŞİMŞEK, (Hacettepe Üniversitesi, Tıp Fakültesi Hastanesi, İç Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Gülay SAİN GÜVEN (Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Genel Dahiliye Bilim Dalı, Ankara, Türkiye)

Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi

2 1

Yıl: 2021 Cilt: 26 Sayı: 1 Sayfa Aralığı: 12 - 22 Metin Dili: Türkçe DOI: 10.5578/flora.20219902 İndeks Tarihi: 20-05-2021

COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”

Öz:

Birinci yılını geride bıraktığımız Coronavirus Disease-2019 (COVID-19) pandemisinde tıp camiasında tanı ve tedavi konusunda hızlı geliş-meler söz konusu iken, kronik hastalığı ve birden çok ilaç kullanan risk faktörü yüksek hastalarda ilaç etkileşimleri ve yan etkileri sorun oluşturmuştur. Rutin aşı üretim sürecinin aksine bir yıl gibi kısa bir sürede birçok ilaç firmasının geliştirdiği aşılar birçok ülkede uygulanmaya başlanmıştır. Ancak bu süreç mutasyon ve üretim ile dağıtımdaki sıkıntılar nedeniyle kısıtlanmaktadır. Hastalığın patofizyolojisinin tam olarak aydınlatılamamış olması uzamış COVID-19 sendromu tanımını gündeme taşımıştır. Pandeminin birinci yılında geldiğimiz noktada “iyi” ve “kötü” gelişmeler olması, bize Sergio Leone’nin yönettiği 1966 yapımı İyi, Kötü ve Çirkin (The Good, The Bad and The Ugly), filmini çağrıştırdı. Biz de pandemide son durumu aynı başlıklar altında incelemeye karar verdik. Pandemi yılında karşılaştığımız ve tanıklık ettiği-miz birçok gelişme, sorun ve çözüm fikirlerine genel bir bakış kazanmak ve fikir elde etmek sürecin yönetimini daha da kolaylaştıracaktır.

Anahtar Kelime:

“The Good, the Bad and the Ugly” in the First Year of COVID-19 Pandemic

Öz:

During the first year of COVID-19 pandemic, while there have been rapid developments in diagnosis and treatment of the disease; drug interactions and side effects have created a problem especially in high risk patients with chronic diseases and multiple drug use. In contrast to the routine vaccine production process, SARS-CoV-2 vaccines have been developed in a short period of time by many phar-maceutical companies, and community vaccination has started in many countries. However, this process is restricted by mutation and problems in production and distribution. The fact that the pathophysiology of the disease has not been fully elucidated has brought the prolonged COVID-19 syndrome definition to our clinical practice. Positive improvements and negative aspects that we have encountered so far in the first year of this new pandemic reminded us the great film by Sergio Leone: “The Good, The Bad and The Ugly”. So, we decided to cover these aspects under the same headings. Gaining an overview of the many developments, problems and solution ideas we encountered and witnessed during the pandemic year will make the management of the process easier.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. World Health Organization (WHO). Regional Office for Novel Coronavirus (2019-nCoV) Situation Report-51 2020.
2. T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Sayfası. Genel Koronavirüs Tablosu. Erişim tarihi: 06.02.2021. Erişim adresi: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus- tablosu.html.
3. World Health Organization (WHO). COVID-19. Erişim tarihi: 06.02.2021. Erişim adresi: https://covid19.who.int.
4. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020;94:44-8.
5. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect 2020;80(6):e14-e8.
6. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano 2020;14(4):3822-35.
7. Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 2020;9:72.
8. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. Heart Rhythm 2020;17(7):e231-e2.
9. Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID- 19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020;9(1):29.
10. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172(9):577-82.
11. Peng PWH, PL Ho, SS Hota. Outbreak of a new coronavirus: what anaesthetists should know. Br J Anaesth 2020;124(5):497-501.
12. Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al. Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study. medRxiv 2020;23:2020.02.21.20026328.
13. Wax RS, MD C. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth 2020;67(5):568-76.
14. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol 2020;92(7):719-25.
15. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109(5):531-8.
16. Singhal T. A Review of Coronavirus Disease-2019 (COVID- 19). Indian J Pediatr 2020;87(4): 281-6.
17. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020;92(6):552-5.
18. Wu Z, McGoogan JM. characteristics of and ımportant lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-42.
19. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z, et al. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020;35(5):1545-9.
20. Goudouris ES. Laboratory diagnosis of COVID-19. J Pediatr Rio J 2021;97(1):7-12.
21. Watson JP, Whiting F, Brush JE. Interpreting a COVID-19 test result. BMJ 2020;369:m1808.
22. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn 2020;20(5):453-4.
23. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J-B, Olsson A, et al. Robust t cell ımmunity in convalescent ındividuals with asymptomatic or Mild COVID-19. Cell 2020;183(1):158-68.
24. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M-C, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75(7):1564-81.
25. Chen G. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620-9.
26. Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T, Rucci C, et al. Chest CT features of COVID-19 in Rome, Italy. Radiology 2020;296(2):E79-E85.
27. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020;9(1):727-32.
28. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18(4):844-7.
29. Cao B. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382(19):1787-99.
30. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569-78.
31. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) ıs mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9(2).
32. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020;6(10):1192-8.
33. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed date: 18.02.2021. Available from: https://www.covid19treatmentguidelines.nih.gov/.
34. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report. N Engl J Med 2020.
35. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020;117(20): 10970-5.
36. Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Intern Emerg Med 2021;4:1-28.
37. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18(5):1023-6.
39. Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 2020;87:59-73.
39. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID- 19. Front Immunol 2020;11:585354.
40. Jung F, Krieger V, Hufert FT, Küpper J-H. Herd immunity or suppression strategy to combat COVID-19. Clin Hemorheol Microcirc 2020;75(1):13-7.
41. World Health Organization (WHO). Draft landscape and tracker of COVID-19 Candidate Vaccines. WHO. Accessed date: 19.02.2021. Available from: https://www.who.int/ publications/m/item/draft-landscape-of-covid-19-candidate- vaccines.
42. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020;27(3):325-8.
43. Mubarak A, Alturaiki W, Hemida MG. Middle east respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J Immunol Res 2019;2019:6491738.
44. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020;12(3).
45. Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 2021;892:173751.
46. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008;205(1):7-12.
47. Rudvan AL Lİ, Ünal S. Dünyada faz 3 çalışmaları devam eden COVID-19 aşı adaylarının güncel durumu. FLORA 2020;25(4):474-9.
48. Zhao Q. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 2013;31(11):654-63.
49. Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2013;2(8):e52.
50. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 2012;45(12):1102-11.
51. Barria MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013;207(1):115-24.
52. Sohrab SS, Suhail M, Kamal MA, Husen A, Azhar EI. Recent development and future prospects of plant-based vaccines. Curr Drug Metab 2017;18(9):831-41.
53. Kumar A, Meldgaard TS, Bertholet S. Novel platforms for the development of a universal ınfluenza vaccine. Front Immunol 2018;9:600.
54. Türkiye İlaç ve Tıbbi Cihaz Kurumu (TİTCK). Erişim tarihi: 20.02.2021. Erişim adresi: https://www.titck.gov.tr/haber/ kamuoyunun-dikkatine-13012021185623.
55. https://covid19asi.saglik.gov.tr/TR-77707/asi-uygulanacak- grup-siralamasi.html. 20.02.2021].
56. Gavi, the Vaccine Alliance. Accessed date: 20.02.2021. Available from: https://www.gavi.org/.
57. Deng L, Li C, Zeng Q, Liu X, Zhang H, Hong Z, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect 2020;81(1):e1-e5.
58. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020;382(25):2411-8.
59. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med 2015;13:74.
60. Aygun I, Kaya M, Alhajj R. Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep 2020;10(1):21508.
61. Mahase E. Covid-19: What do we know about “long covid”? BMJ 2020;370:m2815.
62. Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, Steig B, Gaini S, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clin Infect Dis 2020;ciaa1792.
63. Mahase E. Long covid could be four different syndromes, review suggests. BMJ 2020;371:m3981.
64. Wang R, Hozumi Y, Yin C, Wei G-W. Decoding SARS-CoV-2 transmission and evolution and ramifications for COVID- 19 diagnosis, vaccine, and medicine. J Chem Inf Model 2020;60(12):5853-65.
65. Yurkovetskiy L, Pascal KE, Tomkins C, Nyalile T, Wang Y, Baum A, et al. SARS-CoV-2 spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain. bioRxiv 2020;183:739-51.
66. Wang R, Chen J, Gao K, Yin C, Wei G-W. Analysis of SARSCoV- 2 mutations in the United States suggests presence of four substrains and novel variants. Commun Biol 2021;4(1):228.

APA	Kapar B, ŞİMŞEK D, SAINGUVEN G (2021). COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. , 12 - 22. 10.5578/flora.20219902
Chicago	Kapar Berkay,ŞİMŞEK DENİZ,SAINGUVEN GULAY COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. (2021): 12 - 22. 10.5578/flora.20219902
MLA	Kapar Berkay,ŞİMŞEK DENİZ,SAINGUVEN GULAY COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. , 2021, ss.12 - 22. 10.5578/flora.20219902
AMA	Kapar B,ŞİMŞEK D,SAINGUVEN G COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. . 2021; 12 - 22. 10.5578/flora.20219902
Vancouver	Kapar B,ŞİMŞEK D,SAINGUVEN G COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. . 2021; 12 - 22. 10.5578/flora.20219902
IEEE	Kapar B,ŞİMŞEK D,SAINGUVEN G "COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”." , ss.12 - 22, 2021. 10.5578/flora.20219902
ISNAD	Kapar, Berkay vd. "COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”". (2021), 12-22. https://doi.org/10.5578/flora.20219902

APA	Kapar B, ŞİMŞEK D, SAINGUVEN G (2021). COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 26(1), 12 - 22. 10.5578/flora.20219902
Chicago	Kapar Berkay,ŞİMŞEK DENİZ,SAINGUVEN GULAY COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 26, no.1 (2021): 12 - 22. 10.5578/flora.20219902
MLA	Kapar Berkay,ŞİMŞEK DENİZ,SAINGUVEN GULAY COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.26, no.1, 2021, ss.12 - 22. 10.5578/flora.20219902
AMA	Kapar B,ŞİMŞEK D,SAINGUVEN G COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2021; 26(1): 12 - 22. 10.5578/flora.20219902
Vancouver	Kapar B,ŞİMŞEK D,SAINGUVEN G COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2021; 26(1): 12 - 22. 10.5578/flora.20219902
IEEE	Kapar B,ŞİMŞEK D,SAINGUVEN G "COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 26, ss.12 - 22, 2021. 10.5578/flora.20219902
ISNAD	Kapar, Berkay vd. "COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 26/1 (2021), 12-22. https://doi.org/10.5578/flora.20219902